$VASO
VASO Corp Stock $vaso

$vaso Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000121390024028734 Filed on April 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$18.74M	$21.92M	$81.02M
YoY Change	-2.51%	-6.62%	1.26%
Cost Of Revenue	$7.820M	$7.864M	$30.43M
YoY Change	4.11%	-8.88%	-3.5%
Gross Profit	$10.92M	$14.05M	$50.59M
YoY Change	-6.76%	-5.3%	4.36%
Gross Profit Margin	58.27%	64.12%	62.44%
Selling, General & Admin	$12.20M	$12.91M	$45.64M
YoY Change	9.44%	14.68%	11.75%
% of Gross Profit	111.7%	91.88%	90.22%
Research & Development	$191.0K	$171.0K	$755.0K
YoY Change	21.66%	-6.56%	24.79%
% of Gross Profit	1.75%	1.22%	1.49%
Depreciation & Amortization	$185.0K	$239.0K	$999.0K
YoY Change	-32.23%	-31.12%	-48.05%
% of Gross Profit	1.69%	1.7%	1.97%
Operating Expenses	$12.39M	$13.08M	$46.40M
YoY Change	9.61%	14.34%	11.94%
Operating Profit	-$1.468M	$970.0K	$4.195M
YoY Change	-458.05%	-71.45%	-40.35%
Interest Expense	$308.0K	$177.0K	$714.0K
YoY Change	460.0%	331.71%	621.21%
% of Operating Profit		18.25%	17.02%
Other Income/Expense, Net	$307.0K		$710.0K
YoY Change	468.52%		631.96%
Pretax Income	-$1.161M	$1.146M	$4.905M
YoY Change	-350.22%	-66.68%	-31.21%
Income Tax	$12.00K	$65.00K	$100.0K
% Of Pretax Income		5.67%	2.04%
Net Earnings	-$1.173M	$1.081M	$4.805M
YoY Change	-358.37%	-86.86%	-59.53%
Net Earnings / Revenue	-6.26%	4.93%	5.93%
Basic Earnings Per Share	-$0.01		$0.03
Diluted Earnings Per Share	-$0.01	$0.01	$0.03
COMMON SHARES
Basic Shares Outstanding	175.3M shares	175.3M shares	174.4M shares
Diluted Shares Outstanding	175.1M shares		175.5M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$23.77M	$25.32M	$25.32M
YoY Change	30.23%	24.58%	24.58%
Cash & Equivalents	$19.54M	$11.34M	$11.34M
Short-Term Investments	$4.235M	$13.98M	$13.98M
Other Short-Term Assets	$5.143M	$5.002M	$5.002M
YoY Change	8.59%	17.5%	17.5%
Inventory	$1.566M	$1.470M	$1.470M
Prepaid Expenses
Receivables	$7.465M	$12.38M	$12.38M
Other Receivables	$1.053M	$929.0K	$929.0K
Total Short-Term Assets	$39.00M	$45.10M	$45.10M
YoY Change	1.6%	7.38%	7.38%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.302M	$3.123M	$3.123M
YoY Change	-0.31%	133.06%	7.39%
Goodwill	$15.56M	$15.59M
YoY Change	-0.4%	-0.17%
Intangibles	$1.424M	$1.406M
YoY Change		-6.95%
Long-Term Investments	$652.0K	$683.0K	$683.0K
YoY Change	-19.61%	-23.17%	-23.17%
Other Assets	$4.724M	$9.858M	$9.858M
YoY Change	-11.47%	108.59%	1.28%
Total Long-Term Assets	$30.45M	$30.66M	$30.66M
YoY Change	-2.15%	0.01%	0.01%
TOTAL ASSETS
Total Short-Term Assets	$39.00M	$45.10M	$45.10M
Total Long-Term Assets	$30.45M	$30.66M	$30.66M
Total Assets	$69.44M	$75.76M	$75.76M
YoY Change	-0.08%	4.27%	4.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.976M	$2.670M	$2.670M
YoY Change	33.09%	17.62%	17.62%
Accrued Expenses	$4.694M	$8.662M	$8.662M
YoY Change	-21.45%	-30.79%	-30.79%
Deferred Revenue		$15.88M
YoY Change
Short-Term Debt	$3.000K	$3.000K	$3.000K
YoY Change	0.0%	0.0%	0.0%
Long-Term Debt Due	$222.0K	$81.00K	$81.00K
YoY Change	119.8%	-38.17%	-38.17%
Total Short-Term Liabilities	$27.28M	$30.04M	$30.04M
YoY Change	4.01%	-5.26%	-5.26%
LONG-TERM LIABILITIES
Long-Term Debt	$9.000K	$31.00K	$31.00K
YoY Change	-90.11%	-72.07%	-72.07%
Other Long-Term Liabilities	$1.487M	$18.84M	$18.84M
YoY Change	-11.28%	1178.36%	4.91%
Total Long-Term Liabilities	$16.59M	$18.87M	$18.87M
YoY Change	-16.7%	4.44%	4.44%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.28M	$30.04M	$30.04M
Total Long-Term Liabilities	$16.59M	$18.87M	$18.87M
Total Liabilities	$43.87M	$48.91M	$48.91M
YoY Change	-4.93%	-1.74%	-1.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$36.21M	-$35.03M
YoY Change	-6.14%	-10.24%
Common Stock	$186.0K	$186.0K
YoY Change	0.54%	0.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.000M	$2.000M
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	$25.58M	$26.84M	$26.84M
YoY Change
Total Liabilities & Shareholders Equity	$69.44M	$75.76M	$75.76M
YoY Change	-0.08%	4.27%	4.27%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.173M	$1.081M	$4.805M
YoY Change	-358.37%	-86.86%	-59.53%
Depreciation, Depletion And Amortization	$185.0K	$239.0K	$999.0K
YoY Change	-32.23%	-31.12%	-48.05%
Cash From Operating Activities	-$1.070M	-$1.564M	$5.296M
YoY Change	-44.87%	-189.89%	-63.26%
INVESTING ACTIVITIES
Capital Expenditures	$472.0K	$191.0K	$731.0K
YoY Change	218.92%	60.5%	29.15%
Acquisitions
YoY Change
Other Investing Activities	$9.616M	$2.074M	-$4.926M
YoY Change		-169.09%	-37.26%
Cash From Investing Activities	$9.144M	$1.883M	-$5.657M
YoY Change	-6278.38%	-160.33%	-32.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$121.0K	-24.00K	-134.0K
YoY Change	-352.08%	-54.72%	-41.74%
NET CHANGE
Cash From Operating Activities	-$1.070M	-1.564M	5.296M
Cash From Investing Activities	$9.144M	1.883M	-5.657M
Cash From Financing Activities	$121.0K	-24.00K	-134.0K
Net Change In Cash	$8.194M	295.0K	-495.0K
YoY Change	-480.06%	-120.57%	-108.54%
FREE CASH FLOW
Cash From Operating Activities	-$1.070M	-$1.564M	$5.296M
Capital Expenditures	$472.0K	$191.0K	$731.0K
Free Cash Flow	-$1.542M	-$1.755M	$4.565M
YoY Change	-26.18%	-208.27%	-67.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	0-18105
CY2023	dei	Entity Registrant Name EntityRegistrantName	VASO CORPORATION
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	11-2871434
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	137 Commercial
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Street,
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Plainview
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11803
CY2023	dei	City Area Code CityAreaCode	(516)
CY2023	dei	Local Phone Number LocalPhoneNumber	997-4600
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $.001 par value
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	24300000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	175319296	shares
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	1195
CY2023	dei	Auditor Name AuditorName	UHY LLP
CY2023	dei	Auditor Location AuditorLocation	Sterling Heights, Michigan
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	11342000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	11821000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	13979000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	8504000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	9708000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6947000	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	12377000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	14514000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1470000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1473000	usd
CY2023Q4	vaso	Deferred Commission Expensecurrent DeferredCommissionExpensecurrent	3285000	usd
CY2022Q4	vaso	Deferred Commission Expensecurrent DeferredCommissionExpensecurrent	3249000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1717000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1008000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	45099000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	40990000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10358000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9787000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1174000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1340000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1949000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1568000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	15588000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	15614000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1406000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1511000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4902000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4726000	usd
CY2023Q4	vaso	Investment In Enhanced External Counterpulsation Global InvestmentInEnhancedExternalCounterpulsationGlobal	683000	usd
CY2022Q4	vaso	Investment In Enhanced External Counterpulsation Global InvestmentInEnhancedExternalCounterpulsationGlobal	889000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	4956000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	5007000	usd
CY2023Q4	us-gaap	Assets Assets	75757000	usd
CY2022Q4	us-gaap	Assets Assets	71645000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2670000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2270000	usd
CY2023Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	2411000	usd
CY2022Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	3518000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7365000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	8891000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	72000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	122000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	928000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	745000	usd
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	699000	usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	809000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	15883000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	15139000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	9000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	9000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	30040000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31506000	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	6000	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	15000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	25000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	96000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1020000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	823000	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	16317000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	15664000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1506000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1474000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	18874000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	18072000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	185627383	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	185435965	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	175319296	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	175127878	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	186000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	185000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	63993000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	63952000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-35032000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39837000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-304000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-233000	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	10308087	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	10308087	shares
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2000000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2000000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	26843000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	22067000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	75757000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	71645000	usd
CY2023	us-gaap	Revenues Revenues	81024000	usd
CY2022	us-gaap	Revenues Revenues	79294000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	30431000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	31392000	usd
CY2023	us-gaap	Gross Profit GrossProfit	50593000	usd
CY2022	us-gaap	Gross Profit GrossProfit	47902000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	45643000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40843000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	755000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	605000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	46398000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	41448000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	4195000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	6454000	usd
CY2023	us-gaap	Interest And Debt Expense InterestAndDebtExpense	50000	usd
CY2022	us-gaap	Interest And Debt Expense InterestAndDebtExpense	44000	usd
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	764000	usd
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	143000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-4000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-2000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	710000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	97000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4905000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6551000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4743000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	4805000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	11294000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-71000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-343000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	4734000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	10951000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.06
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	174441000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	173065000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	175541000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	174656000	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	11081000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	35000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-343000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	11294000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	22067000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	22067000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	48000	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-6000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-71000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	4805000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	26843000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	4805000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	11294000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	999000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1923000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	51000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4788000	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	-206000	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-154000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	66000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	63000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	48000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	35000	usd
CY2023	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-2062000	usd
CY2022	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-480000	usd
CY2023	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	498000	usd
CY2022	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	343000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	22000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	416000	usd
CY2023	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-36000	usd
CY2022	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	300000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1271000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	103000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	213000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2422000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	402000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-521000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1068000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	950000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1549000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1392000	usd
CY2023	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-105000	usd
CY2022	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	108000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1397000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	5838000	usd
CY2023	vaso	Increase Decrease In Due To Related Party IncreaseDecreaseInDueToRelatedParty	-10000	usd
CY2022	vaso	Increase Decrease In Due To Related Party IncreaseDecreaseInDueToRelatedParty	-14000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	32000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	486000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	5296000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	14416000	usd
CY2023	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	731000	usd
CY2022	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	566000	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	24473000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	8000000	usd
CY2023	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	19547000	usd
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	149000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5657000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8417000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	6000	usd
CY2023	vaso	Repayment Of Notes Payable And Finance Lease Obligations RepaymentOfNotesPayableAndFinanceLeaseObligations	128000	usd
CY2022	vaso	Repayment Of Notes Payable And Finance Lease Obligations RepaymentOfNotesPayableAndFinanceLeaseObligations	230000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-134000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-230000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-479000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5796000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11821000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6025000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11342000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11821000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	17000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	44000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	89000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	48000	usd
CY2023	vaso	Initial Recognition Of Operating Lease Right Of Use Asset And Liability InitialRecognitionOfOperatingLeaseRightOfUseAssetAndLiability	1174000	usd
CY2022	vaso	Initial Recognition Of Operating Lease Right Of Use Asset And Liability InitialRecognitionOfOperatingLeaseRightOfUseAssetAndLiability	1396000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE A – DESCRIPTION OF BUSINESS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaso Corporation was incorporated in Delaware in July 1987. For most of its history, the Company was a single-product company designing, manufacturing, marketing and servicing its proprietary Enhanced External Counterpulsation, or EECP<sup>®</sup>, therapy systems, mainly for the treatment of angina. In 2010 it began to diversify its business operations. The Company changed its name to Vaso Corporation in 2016 to more accurately reflect the diversified nature of its business mixture, and continues to use the original name VasoMedical for its proprietary medical device subsidiary. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vaso” or “management” refer to Vaso Corporation and its subsidiaries.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overview</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaso Corporation principally operates in three distinct business segments in the healthcare equipment and information technology industries. We manage and evaluate our operations, and report our financial results, through these three business segments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc., primarily focuses on healthcare IT and managed network technology services;</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional sales service segment, operating through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, primarily focuses on the sale of healthcare capital equipment for GE HealthCare (“GEHC”) into the health provider middle market; and</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment segment, primarily focuses on the design, manufacture, sale and service of proprietary medical devices and software, operating through a wholly-owned subsidiary VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. for domestic business and Vasomedical Global Corp. for international business, respectively.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>VasoTechnology</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VasoTechnology, Inc. was formed in May 2015, at the time the Company acquired all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services, LLC (collectively, “NetWolves”). It currently consists of a managed network and security service division, NetWolves, and a healthcare IT application VAR (value added reseller) division, VasoHealthcare IT.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2014, the Company began its IT segment business by executing the Value Added Reseller Agreement (“VAR Agreement”) with GEHC to become a national value added reseller of GEHC Digital’s software solutions such as Picture Archiving and Communication System (“PACS”), Radiology Information System (“RIS”), and related services, including implementation, training, management and support. This business focuses primarily on customer segments currently served by VasoHealthcare on behalf of GEHC. A new wholly owned subsidiary, VasoHealthcare IT Corp. (“VHC IT”), was formed to conduct the healthcare IT business. The VAR Agreement with GEHC was terminated in 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2015, the Company further expanded its IT segment business by acquiring NetWolves. NetWolves designs and delivers multi-network and multi-technology solutions as a managed network provider, and provides a complete single-source solution that includes design, network redundancy, application device management, real-time network monitoring, reporting and support systems as a comprehensive solution.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>VasoHealthcare</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2010, the Company launched its Professional Sales Service business through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, which was appointed by GEHC as its exclusive representative for the sale of select GEHC diagnostic imaging equipment to specific market segments in the 48 contiguous states of the United States and the District of Columbia. The original agreement (“GEHC Agreement”) has been extended several times and currently expires December 31, 2026, subject to earlier termination under certain conditions. The scope of the agreement has also been expanded in 2023 to include ultrasound systems.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>VasoMedical</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The proprietary medical equipment business under VasoMedical traces back to 1995 when the Company began the proprietary Enhanced External Counterpulsation (EECP<sup>®</sup>) technology in the United States and has since diversified to include other medical hardware and software. Vasomedical Global was formed in 2011 to combine and coordinate the various international operations including design, development, manufacturing, and sales of medical devices and software, while domestic activities are conducted under Vasomedical Solutions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over the last 10+ years the Company’s Equipment business has been significantly expanded from the original EECP<sup>®</sup>-only operations. In September 2011, the Company acquired Fast Growth Enterprises Limited (“FGE”), a British Virgin Islands company, which owned or controlled two Chinese operating companies - Life Enhancement Technology Ltd. (“LET”) and Biox Instruments Co. Ltd. (“Biox”) - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio. Biox was a variable interest entity (“VIE”) controlled by FGE through certain contracts and an option to acquire all the shares of Biox by FGE’s wholly owned subsidiary Gentone, and in March 2019 Gentone exercised its option to acquire all of the shares of Biox. In August 2014, the Company, through Gentone, acquired all of the outstanding shares of Genwell Instruments Co. Ltd. (“Genwell”), which was formed in China in 2010 to develop the MobiCare<sup>®</sup> wireless multi-parameter patient monitoring system and holds intellectual property rights for this system. As a result, the Company has expanded its equipment products portfolio to include Biox™ series ambulatory patient monitoring systems, ARCS<sup>®</sup> series software for ECG and blood pressure analysis, and the MobiCare<sup>®</sup> patient monitoring device.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2014, the Company entered into a cooperation agreement with Chongqing PSK-Health Sci-Tech Development Co., Ltd. (“PSK”) of Chongqing, China, the leading manufacturer of external counter pulsation, or ECP, therapy systems in China, to form a joint venture company, VSK Medical Limited (“VSK”), a Cayman Islands company, for the global marketing, sale and advancement of ECP therapy technology. The Company owned 49.9% of VSK, which commenced operations in January 2015. In March 2018, the Company terminated the cooperation agreement with PSK and sold its shares in VSK to PSK. On May 20, 2020, the Company closed on the sale of 51% of the capital stock of its wholly-owned subsidiary EECP Global Corporation (“EECP Global”) to PSK. EECP Global was formed in September 2019 to hold all the assets and liabilities of its EECP business. Concurrently with the closing of the transaction, the Company signed a Management Service Agreement with EECP Global to provide management service for the business and operation of EECP Global in the United States. The agreement provides an initial term of three years starting April 1, 2020, the effective date of the sale, which is automatically renewable for additional one-year terms. Pursuant to the agreement, EECP Global reimburses the Company all direct expenses and pays a monthly management fee during the term of the agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Achari Business Combination Agreement</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As previously announced, the Company entered into a business combination agreement (the “Business Combination Agreement”), dated as of December 6, 2023, with Achari Ventures Holdings Corp. I, a Delaware corporation (“Achari”) (NASDAQ: AVHI), and Achari Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Achari (“Merger Sub”). The Business Combination Agreement provides, among other things, that on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving as a wholly owned subsidiary of Achari. Upon the closing of the Business Combination Agreement (the “Closing”), we anticipate that Achari will change its name to “Vaso Holdings Corp.” or an alternative name chosen by the Company and reasonably acceptable to Achari (“New Vaso”). The Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to collectively as the “Business Combination”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the Closing, New Vaso would have authorized shares of Class A common stock and Class B common stock. The Business Combination Agreement establishes a pro forma equity value of the Company at approximately $176 million, at $10.00 per share of Class A common stock. As such, we believe that the current Vaso stockholders would receive approximately 17.6 million shares of Class A common stock and the current Achari shareholders would maintain between 500 thousand and 750 thousand shares of Class A common stock depending on Achari’s unpaid expenses at the Closing and presuming the redemption of all outstanding public shares of Achari on or prior to the Closing. In addition, current Achari warrant holders would have outstanding warrants to purchase a minimum of 8.25 million shares of Class A common stock at an exercise price of $11.50 per share. No shares of Class B common stock are expected to be outstanding immediately after the Business Combination.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Boards of Directors of Vaso and Achari have each approved the Business Combination, the consummation of which is subject to various customary closing conditions, including the filing and effectiveness of a Registration Statement on Form S-4 (as amended or supplemented, the “Registration Statement”) by Achari with the United States Securities and Exchange Commission (“SEC”), the filing of a proxy statement by Vaso with the SEC and clearance by the SEC, and the approval of a majority of shareholders of both Achari and Vaso of the proposed business combination (Vaso shareholders representing approximately 44% of Vaso’s outstanding shares have entered into support agreements committing them to vote in favor of the Business Combination). The Business Combination is expected to close in the second quarter of 2024.</p>
CY2015Q1	us-gaap	Sale Of Stock Percentage Of Ownership Before Transaction SaleOfStockPercentageOfOwnershipBeforeTransaction	0.499	pure
CY2020Q2	us-gaap	Sale Of Stock Percentage Of Ownership After Transaction SaleOfStockPercentageOfOwnershipAfterTransaction	0.51	pure
CY2020Q2	vaso	Initial Term InitialTerm	P3Y
CY2023	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	176000000	usd
CY2023	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	10
CY2023	us-gaap	Amount Of Regulatory Assistance Received1 AmountOfRegulatoryAssistanceReceived1	17600000	usd
CY2023	us-gaap	Dividends Common Stock Stock DividendsCommonStockStock	500000	usd
CY2023	us-gaap	Stock Dividends Shares StockDividendsShares	750000	shares
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	8250000	usd
CY2023	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	11.5
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	229000000	usd
CY2022Q1	us-gaap	Brokerage Commissions Revenue BrokerageCommissionsRevenue	287000000	usd
CY2022Q1	us-gaap	Leasing Commissions Expense LeasingCommissionsExpense	58000000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions relate to estimates of commission adjustments due to order cancellations, collectability of accounts receivable, the realizability of deferred tax assets, stock-based compensation, values and lives assigned to acquired intangible assets, fair value of reporting units in connection with goodwill impairment test, the adequacy of inventory reserves, variable consideration, and allocation of contract transaction price to performance obligations. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023	us-gaap	Revenues Revenues	81024000	usd
CY2022	us-gaap	Revenues Revenues	79294000	usd
CY2023	us-gaap	Revenues Revenues	81024000	usd
CY2022	us-gaap	Revenues Revenues	79294000	usd
CY2023	vaso	Recognize Revenue RecognizeRevenue	95000000	usd
CY2022Q4	vaso	Transaction Price TransactionPrice	91000000	usd
CY2022Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	15306000	usd
CY2021Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	15474000	usd
CY2023Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	13398000	usd
CY2022Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	15306000	usd
CY2023	vaso	Increase Decrease Contract Receivable IncreaseDecreaseContractReceivable	-1909000	usd
CY2022	vaso	Increase Decrease Contract Receivable IncreaseDecreaseContractReceivable	-168000	usd
CY2022Q4	vaso	Contract Liabilities ContractLiabilities	33861000	usd
CY2021Q4	vaso	Contract Liabilities ContractLiabilities	26890000	usd
CY2023Q4	vaso	Contract Liabilities ContractLiabilities	33589000	usd
CY2022Q4	vaso	Contract Liabilities ContractLiabilities	33861000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-272000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	6971000	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	9200000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	9100000	usd
CY2023	us-gaap	Contract With Customer Asset Reclassified To Receivable ContractWithCustomerAssetReclassifiedToReceivable	2561000	usd
CY2022	us-gaap	Contract With Customer Asset Reclassified To Receivable ContractWithCustomerAssetReclassifiedToReceivable	2732000	usd
CY2023	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	7106000	usd
CY2022	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	7113000	usd
CY2023Q4	vaso	Deferred Commission Expense DeferredCommissionExpense	3285000	usd
CY2022Q4	vaso	Deferred Commission Expense DeferredCommissionExpense	3249000	usd
CY2023Q4	vaso	Deferred Longterm Portion DeferredLongtermPortion	3821000	usd
CY2022Q4	vaso	Deferred Longterm Portion DeferredLongtermPortion	3864000	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	3000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	5000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	114000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	13555000	usd
CY2023Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	13559000	usd
CY2023	vaso	Trading Securities Unrealized Holding Loss Amount TradingSecuritiesUnrealizedHoldingLossAmount	4000	usd
CY2023Q4	us-gaap	Deposits Fair Value Disclosure DepositsFairValueDisclosure	424000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	10522000	usd
CY2023Q4	us-gaap	Deposits Fair Value Disclosure DepositsFairValueDisclosure	424000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	10946000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	7934000	usd
CY2022Q4	us-gaap	Deposits Fair Value Disclosure DepositsFairValueDisclosure	433000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	8367000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	6947000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	5804000	usd
CY2023	vaso	Provision For Losses On Accounts Receivable ProvisionForLossesOnAccountsReceivable	66000	usd
CY2022	vaso	Provision For Losses On Accounts Receivable ProvisionForLossesOnAccountsReceivable	63000	usd
CY2023	vaso	Allowance For Doubtful Accounts Receivable Charge Offs Net Of Recoveries AllowanceForDoubtfulAccountsReceivableChargeOffsNetOfRecoveries	-60000	usd
CY2022	vaso	Allowance For Doubtful Accounts Receivable Charge Offs Net Of Recoveries AllowanceForDoubtfulAccountsReceivableChargeOffsNetOfRecoveries	-159000	usd
CY2023	vaso	Allowance For Doubtful Accounts Receivable Commission Adjustment AllowanceForDoubtfulAccountsReceivableCommissionAdjustment	2755000	usd
CY2022	vaso	Allowance For Doubtful Accounts Receivable Commission Adjustment AllowanceForDoubtfulAccountsReceivableCommissionAdjustment	1239000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	9708000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	6947000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentrations of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We market our equipment and IT software solutions principally to hospitals, diagnostic imaging centers and physician private practices. We perform credit evaluations of our customers’ financial condition and, as a result, believe that our receivable credit risk exposure is limited. For the years ended December 31, 2023 and 2022, no customer in our equipment or IT segment accounted for 10% or more of revenues or accounts receivable. In our professional sales service segment, 100% of our revenues and accounts receivable are with GEHC; however, we believe this risk is acceptable based on GEHC’s financial position and our long history of doing business with GEHC.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash balances in certain U.S. financial institutions which exceed the Federal Depository Insurance Corporation (“FDIC”) coverage of $250,000 by approximately $10,054,000. The Company has not experienced any losses on these accounts and believes it is not subject to any significant credit risk on these accounts. In addition, the FDIC does not insure the Company’s foreign bank balances, which aggregated approximately $467,000 and $1,234,000 at December 31, 2023 and 2022, respectively.</span></p>
CY2023	us-gaap	Insurance Commissions And Fees InsuranceCommissionsAndFees	10054000	usd
CY2023Q4	us-gaap	Deposits Foreign DepositsForeign	467000	usd
CY2022Q4	us-gaap	Deposits Foreign DepositsForeign	1234000	usd
CY2023	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	253000	usd
CY2022	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	0	usd
CY2023	vaso	Deferred Tax Asset Percentage DeferredTaxAssetPercentage	0.50	pure
CY2023	us-gaap	Other Comprehensive Income Other Net Of Tax OtherComprehensiveIncomeOtherNetOfTax	71000	usd
CY2022	us-gaap	Other Comprehensive Income Other Net Of Tax OtherComprehensiveIncomeOtherNetOfTax	343000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	174441000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	173065000	shares
CY2023	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	1100000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	1591000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	175541000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	174656000	shares
CY2023	us-gaap	Revenues Revenues	81024000	usd
CY2022	us-gaap	Revenues Revenues	79294000	usd
CY2023	us-gaap	Gross Profit GrossProfit	50593000	usd
CY2022	us-gaap	Gross Profit GrossProfit	47902000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	4195000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	6454000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	999000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1923000	usd
CY2023	us-gaap	Capital Expenditure Discontinued Operations CapitalExpenditureDiscontinuedOperations	731000	usd
CY2022	us-gaap	Capital Expenditure Discontinued Operations CapitalExpenditureDiscontinuedOperations	566000	usd
CY2023Q4	us-gaap	Assets Assets	75757000	usd
CY2022Q4	us-gaap	Assets Assets	71645000	usd
CY2023	us-gaap	Revenues Revenues	81024000	usd
CY2022	us-gaap	Revenues Revenues	79294000	usd
CY2023Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	22085000	usd
CY2022Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	21461000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	9708000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6947000	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	12377000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	14514000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	832000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	751000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	11000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	6000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	627000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	716000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1470000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1473000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	164000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	163000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11532000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11127000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10358000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9787000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1174000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1340000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	951000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	858000	usd
CY2023	us-gaap	Depreciation Depreciation	635000	usd
CY2022	us-gaap	Depreciation Depreciation	1372000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	15614000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	15722000	usd
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	26000	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	108000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	15588000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	15614000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1406000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1511000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	361000	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	15000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	551000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	325000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	254000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	199000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	169000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	131000	usd
CY2023Q4	vaso	Finite Lived Intangible Asset Amortization Expense FiniteLivedIntangibleAssetAmortizationExpense	1078000	usd
CY2023Q4	us-gaap	Deferred Costs DeferredCosts	3821000	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	3864000	usd
CY2023Q4	us-gaap	Other Receivable Before Allowance For Credit Loss Noncurrent OtherReceivableBeforeAllowanceForCreditLossNoncurrent	1021000	usd
CY2022Q4	us-gaap	Other Receivable Before Allowance For Credit Loss Noncurrent OtherReceivableBeforeAllowanceForCreditLossNoncurrent	792000	usd
CY2023Q4	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	412000	usd
CY2022Q4	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	412000	usd
CY2023Q4	us-gaap	Other Receivable After Allowance For Credit Loss Noncurrent OtherReceivableAfterAllowanceForCreditLossNoncurrent	60000	usd
CY2022Q4	us-gaap	Other Receivable After Allowance For Credit Loss Noncurrent OtherReceivableAfterAllowanceForCreditLossNoncurrent	70000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4902000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4726000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	30803000	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	24965000	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	32200000	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	24000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	30803000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	15883000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	15139000	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	16317000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	15664000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	2482000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	2652000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	2142000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	2012000	usd
CY2023Q4	vaso	Order Reduction Liability OrderReductionLiability	971000	usd
CY2022Q4	vaso	Order Reduction Liability OrderReductionLiability	2577000	usd
CY2023Q4	us-gaap	Other Liabilities OtherLiabilities	1770000	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	1650000	usd
CY2023Q4	vaso	Accrued Expenses And Other Liabilities AccruedExpensesAndOtherLiabilities	7365000	usd
CY2022Q4	vaso	Accrued Expenses And Other Liabilities AccruedExpensesAndOtherLiabilities	8891000	usd
CY2023	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	0	usd
CY2022	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	95000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	9000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	9000	usd
CY2023Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	6000	usd
CY2022Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	15000	usd
CY2023Q4	us-gaap	Short Term Debt Percentage Bearing Fixed Interest Rate ShortTermDebtPercentageBearingFixedInterestRate	0.019	pure
CY2022Q4	us-gaap	Shortterm Debt Average Outstanding Amount ShorttermDebtAverageOutstandingAmount	3000000	usd
CY2022	vaso	Finance Lease Cost FinanceLeaseCost	198000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	1011000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	878000	usd
CY2023	vaso	Assets And Liabilities Leases Term AssetsAndLiabilitiesLeasesTerm	P12M
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	72000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	122000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	928000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	745000	usd
CY2023Q4	vaso	Lease Liabilities Current LeaseLiabilitiesCurrent	1000000	usd
CY2022Q4	vaso	Lease Liabilities Current LeaseLiabilitiesCurrent	867000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	25000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	96000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1020000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	823000	usd
CY2023Q4	vaso	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	1045000	usd
CY2022Q4	vaso	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	919000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	83000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	932000	usd
CY2023Q4	vaso	Leases Liability Payments Due Next Twelve Months LeasesLiabilityPaymentsDueNextTwelveMonths	1015000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	25000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	697000	usd
CY2023Q4	vaso	Leases Liability Payments Due Year Two LeasesLiabilityPaymentsDueYearTwo	722000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	406000	usd
CY2023Q4	vaso	Leases Liability Payments Due Year Three LeasesLiabilityPaymentsDueYearThree	406000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	124000	usd
CY2023Q4	vaso	Leases Liability Payments Due Year Four LeasesLiabilityPaymentsDueYearFour	124000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	108000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2159000	usd
CY2023Q4	vaso	Leases Liability Payments Due LeasesLiabilityPaymentsDue	2267000	usd
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	11000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	211000	usd
CY2023Q4	vaso	Leases Liability Undiscounted Excess Amount LeasesLiabilityUndiscountedExcessAmount	222000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	97000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1948000	usd
CY2023Q4	vaso	Leases Liability LeasesLiability	2045000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	107000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	154000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	23000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	44000	usd
CY2023	vaso	Finance Lease Cost FinanceLeaseCost	130000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	52000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	52000	usd
CY2023	us-gaap	Lease Cost LeaseCost	1193000	usd
CY2022	us-gaap	Lease Cost LeaseCost	1128000	usd
CY2023	vaso	Operating Cash Flows From Finance Leases OperatingCashFlowsFromFinanceLeases	144000	usd
CY2022	vaso	Operating Cash Flows From Finance Leases OperatingCashFlowsFromFinanceLeases	44000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1011000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	878000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	119000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	222000	usd
CY2023	vaso	Cash Paid For Amounts Included In Measurement Of Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities	1274000	usd
CY2022	vaso	Cash Paid For Amounts Included In Measurement Of Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities	1144000	usd
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P16M
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P23M
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P31M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P30M
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.164	pure
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.142	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.084	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.091	pure
CY2020Q2	vaso	Sale Of Capital Stock Percentage SaleOfCapitalStockPercentage	0.51	pure
CY2020Q2	vaso	Closed On The Sale ClosedOnTheSale	1150000	usd
CY2023	vaso	Withholding Taxrate WithholdingTaxrate	0.10	pure
CY2023	vaso	Reserves Reaches Rate ReservesReachesRate	0.50	pure
CY2023Q4	vaso	Statutory Reserves StatutoryReserves	35000	usd
CY2022Q4	vaso	Statutory Reserves StatutoryReserves	35000	usd
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7500000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	759120	shares
CY2023	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	3540	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7500000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	225000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15000000	shares
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-1000	usd
CY2023Q4	vaso	Remaining Authorized Shares Of Common Stock RemainingAuthorizedSharesOfCommonStock	54317575	shares
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	5085000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	6244000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-180000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	307000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4905000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6551000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	50000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	36000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-1000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	9000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	49000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	45000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	40000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-3724000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	11000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1064000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	51000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4788000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4743000	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0204	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.724	pure
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Settlements State And Local IncomeTaxReconciliationTaxSettlementsStateAndLocal	50000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	51000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4743000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Settlements State And Local IncomeTaxReconciliationTaxSettlementsStateAndLocal	36000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	9000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0619	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0611	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1796	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.9263	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0271	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0081	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.0187	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.0058	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0071	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0022	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.0706	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.0687	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0204	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.724	pure
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11547000	usd
CY2023Q4	vaso	Decrease In Deferred Tax Assets DecreaseInDeferredTaxAssets	459000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3663000	usd
CY2023	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	880000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6796000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8367000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	590000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	328000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	4000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	7000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	100000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	99000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	46000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	46000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	324000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	416000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	855000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	908000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	13000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2819000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1835000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11547000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	12006000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3663000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4543000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	7884000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	7463000	usd
CY2023Q4	vaso	Deferred Tax Liabilities Deferred Commissions DeferredTaxLiabilitiesDeferredCommissions	-701000	usd
CY2022Q4	vaso	Deferred Tax Liabilities Deferred Commissions DeferredTaxLiabilitiesDeferredCommissions	-464000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	2221000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	1962000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	7000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	30000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2929000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2456000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	4955000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5007000	usd
CY2023Q4	us-gaap	Deferred Income Taxes And Other Assets Noncurrent DeferredIncomeTaxesAndOtherAssetsNoncurrent	4955000	usd
CY2022Q4	us-gaap	Deferred Income Taxes And Other Assets Noncurrent DeferredIncomeTaxesAndOtherAssetsNoncurrent	5007000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	4955000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5007000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4543000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10769000	usd
CY2022	vaso	Partial Release Of Allowance PartialReleaseOfAllowance	-4840000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-880000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1386000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3663000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4543000	usd
CY2023	vaso	Net Operating Loss Carryforward Expiration Date NetOperatingLossCarryforwardExpirationDate	expiring at various dates from 2023 through 2037
CY2019Q2	us-gaap	Officers Compensation OfficersCompensation	500000	usd
CY2023	us-gaap	Officers Compensation OfficersCompensation	350000	usd
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.80	pure
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	234000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	112000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation		usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2023Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued		usd
CY2022Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued		usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount		shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount		shares
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree		usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards		usd
CY2023Q4	us-gaap	Deferred Income Taxes And Other Liabilities Noncurrent DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent		usd
CY2022Q4	us-gaap	Deferred Income Taxes And Other Liabilities Noncurrent DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent		usd
CY2023	vaso	Partial Release Of Allowance PartialReleaseOfAllowance		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000839087
CY2023	dei	No Trading Symbol Flag NoTradingSymbolFlag	true
CY2023	dei	Security Exchange Name SecurityExchangeName	NONE

Files In Submission

Name	View Source	Status
0001213900-24-028734-index-headers.html	Edgar Link	pending
0001213900-24-028734-index.html	Edgar Link	pending
0001213900-24-028734.txt	Edgar Link	pending
0001213900-24-028734-xbrl.zip	Edgar Link	pending
ea0202244-10k_vasocorp.htm	Edgar Link	pending
ea020224401ex21_vasocorp.htm	Edgar Link	pending
ea020224401ex31_vasocorp.htm	Edgar Link	pending
ea020224401ex32_vasocorp.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ea0202244-10k_vasocorp_htm.xml	Edgar Link	completed
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vaso-20231231.xsd	Edgar Link	pending
vaso-20231231_cal.xml	Edgar Link	unprocessable
vaso-20231231_pre.xml	Edgar Link	unprocessable
vaso-20231231_lab.xml	Edgar Link	unprocessable
vaso-20231231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VASO
VASO Corp Stock $vaso

2024 Q1 Form 10-K Financial Statement

#000121390024028734 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VASO VASO Corp Stock $vaso

2024 Q1 Form 10-K Financial Statement

#000121390024028734 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VASO
VASO Corp Stock $vaso